← Trials/Trial dossier/NCT00581867

MAIN

CompletedPhase 1 / PHASE2Results posted

Memory and Insulin in Early Alzheimer's Disease

Intranasal Insulin and Memory in Early Alzheimer's Disease

Lead sponsor

Jeff Burns, MD

Asset

Insulin aspart

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Age ≥60

Primary endpoint

•FMRI Measure of Hippocampal Activation

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID10896

NCT IDNCT00581867

Timeline

Milestones

Study start2007-10 (month precision)

Study first posted2007-12-28estimated

Primary completion2012-05actual (month precision)

Study completion2012-05actual (month precision)

Last update posted2015-07-14estimated

Results first posted2015-07-14estimated

Assets

Drug assets

Insulin aspart

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age60 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Patients with Early Alzheimer's disease

Exclusion criteria

•Patients with Late Alzheimer's disease

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition

Neuroimaging

Global cognition

2 endpoints

Secondary/protocol endpoint

Global Cognition

Time frame:90 mins

Mini-Mental State Examination (MMSE)

descriptive

Secondary/registry result

Global Cognition

Time frame:90 mins

Mini-Mental State Examination (MMSE)

descriptive

Posted result

Group	Value (mean), z-scores	Standard deviation
Intranasal Insulin Aspartn=29 Participants	-.05	1.15
Placebon=29 Participants	-.02	1.11

Neuroimaging

2 endpoints

Primary/protocol endpoint

fMRI Measure of Hippocampal Activation

Time frame:30 minutes After Intervention Administration

descriptive

Primary/registry result

fMRI Measure of Hippocampal Activation

Time frame:30 minutes After Intervention Administration

descriptive

Posted result

Group	Value (mean), percentage of active voxels	Standard deviation
Intranasal Insulin Aspartn=29 Participants	36.4	31.4
Placebon=29 Participants	41.3	33.5

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.